Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: A single-center real-world data

Since the results of the ToGA trial were published, trastuzumab-based chemotherapy has been used as the standard first-line treatment for HER2-positive recurrent or primary metastatic gastric cancer (RPMGC).